Keyword: Xtandi

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

Opdivo is priced in China at half its U.S. cost; Novartis names new chief for scandal-hit Korea unit; GSK's Indian consumer unit attracts new buyers.

Pfizer and Astellas are picking up the pace on Xtandi's bid for approval in hormone-sensitive prostate cancer as its new J&J rival Erleada revs up.

Pfizer halts production at a legacy Hospira plant; China works to offer Indian drugmakers streamlined access; Roivant's Sinovant debuts with 11 assets.

Pfizer and Astellas’ prostate cancer med Xtandi nabbed broader FDA approval, setting it up for a head-to-head fight with J&J’s Erleada.

Pfizer CEO Ian Read contends that the company's pipeline is strong enough to fuel growth. In other words, don't look for a "transformative" deal.

With an early approval for its new drug Erleada, J&J just got a head start over Pfizer and Astellas in nonmetastatic prostate cancer.

Pfizer, Astellas and J&J envision a wide-open field for patients whose prostate cancer hasn't spread. But there's a high-stakes market scrum ahead.

Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.

Astellas Oncology's C3 competition featured an AI-powered companion robot and a healthcare professionals’ app to facilitate diagnosis and treatment.